Patient-reported outcomes and early discontinuation in aromatase inhibitor-treated postmenopausal women with early stage breast cancer

Oncologist

Volumn 21, Issue 5, 2016, Pages 539-546

  Kadakia, Kunal C ^a   Snyder, Claire F ^b   Kidwell, Kelley M ^c   Seewald, Nicholas J ^c   Flockhart, David A ^d   Skaar, Todd C ^d   Desta, Zereunesay ^d   Rae, James M ^a   Otte, Julie L ^f   Carpenter, Janet S ^f   Storniolo, Anna M ^e   Hayes, Daniel F ^a   Stearns, Vered ^g   Lynn Henry, Norah ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f INDIANA UNIVERSITY SCHOOL OF NURSING   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Aromatase inhibitors; Early discontinuation; Patient reported outcomes; Quality of life

Indexed keywords

AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; ESTRADIOL; ESTRONE; ESTRONE SULFATE; EXEMESTANE; LETROZOLE; TAMOXIFEN; ESTROGEN;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER STAGING; CENTER FOR EPIDEMIOLOGICAL STUDIES DEPRESSION SCALE; CONTROLLED STUDY; DISTRESS SYNDROME; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MASS FRAGMENTOGRAPHY; MENOPAUSAL SYNDROME; MIDDLE AGED; MUSCULOSKELETAL DISEASE; OUTCOME ASSESSMENT; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SYMPTOM ASSESSMENT; TOXICITY; VISUAL ANALOG SCALE; BREAST NEOPLASMS; METABOLISM; PATHOLOGY; PATIENT-REPORTED OUTCOME; PROSPECTIVE STUDY;

AROMATASE INHIBITORS; BREAST NEOPLASMS; ESTROGENS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PATIENT REPORTED OUTCOME MEASURES; POSTMENOPAUSE; PROSPECTIVE STUDIES;

EID: 84966440379     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2015-0349     Document Type: Article

References (35)

1. Early Breast Cancer Trialists’ Collaborative Group. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 2015;386:1341–1352.
2. Fallowfield L, Cella D, Cuzick J et al. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or inCombination (ATAC) adjuvant breast cancer trial. J Clin Oncol 2004;22:4261–4271.
3. Fallowfield LJ, Bliss JM, Porter LS et al. Quality of life in the intergroup exemestane study: A randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol 2006;24:910–917.
4. Whelan TJ, Goss PE, Ingle JN et al. Assessment of quality of life in MA. 17: A randomized, placebocontrolled trial of letrozole after5years oftamoxifen in postmenopausal women. J Clin Oncol 2005;23: 6931–6940.
5. Murphy CC, Bartholomew LK, Carpentier MY et al. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: A systematic review. Breast Cancer Res Treat 2012; 134:459–478.
6. Henry NL, Azzouz F, Desta Z et al. Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol 2012;30:936–942.
7. Crew KD, Greenlee H, Capodice J et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 2007;25:3877–3883.
8. Kemp A, Preen DB, Saunders C et al. Early discontinuation of endocrine therapy for breast cancer:Whois at risk in clinicalpractice? Springerplus 2014;3:282.
9. Goss PE, Ingle JN, Pritchard KI et al. Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA. 27–a randomized controlled phase III trial. J Clin Oncol 2013;31: 1398–1404.
10. Henry NL, Chan HP, Dantzer J et al. Aromatase inhibitor-induced modulation of breast density: Clinical and genetic effects. Br J Cancer 2013;109: 2331–2339.
11. Pickard AS, Wilke CT, Lin HW et al. Health utilities using the EQ-5D in studies of cancer. Pharmacoeconomics 2007;25:365–384.
12. Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes 2007;5:70.
13. Carpenter JS, Andrykowski MA, Wilson J et al. Psychometrics for two short forms of the Center for Epidemiologic Studies-Depression Scale. Issues Ment Health Nurs 1998;19:481–494.
14. Stafford L, Judd F, Gibson P et al. Comparison of the hospital anxiety and depression scale and the center for epidemiological studies depression scale for detecting depression in women with breast or gynecologic cancer. Gen Hosp Psychiatry 2014;36: 74–80.
15. Ganz PA, Day R, Ware JE Jr. et al. Base-line qualityof- life assessment in the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial. J Natl Cancer Inst 1995;87:1372–1382.
16. Santen RJ, Demers L, Ohorodnik S et al. Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy. Steroids 2007;72:666–671.
17. Desta Z, Kreutz Y, Nguyen AT et al. Plasma letrozole concentrations in postmenopausal women withbreastcancer are associatedwithCYP2A6genetic variants, body mass index, and age. Clin Pharmacol Ther 2011;90:693–700.
18. Cella D, Land SR, Chang CH et al. Symptom measurement in the Breast Cancer Prevention Trial (BCPT) (P-1): Psychometric properties of a new measure of symptoms for midlife women. Breast Cancer Res Treat 2008;109:515–526.
19. Burstein HJ, Temin S, Anderson H et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol 2014;32:2255–2269.
20. Chim K, Xie SX, Stricker CT et al. Jointpainseverity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors. BMC Cancer 2013;13:401.
21. Mao JJ, Stricker C, Bruner D et al. Patterns and risk factors associated with aromatase inhibitorrelated arthralgia among breast cancer survivors. Cancer 2009;115:3631–3639.
22. Henry NL, Conlon A, Kidwell KM et al. Effect of estrogen depletion on pain sensitivity in aromatase inhibitor-treated women with early-stage breast cancer. J Pain 2014;15:468–475.
23. Bauml J, Chen L, Chen J et al. Arthralgia among women takingaromatase inhibitors: Is there a shared inflammatory mechanism with co-morbid fatigue and insomnia? Breast Cancer Res 2015;17:89.
24. Hershman DL, Unger JM, Crew KD et al. Randomized multicenter placebo-controlled trial of omega-3 fatty acids for the control of aromatase inhibitor-induced musculoskeletal pain: SWOG S 0927. J Clin Oncol 2015;33:1910–1917.
25. Hadji P, Blettner M, Harbeck N et al. The Patient’sAnastrozole Compliance to Therapy (PACT) Program: A randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer. Ann Oncol 2013;24:1505–1512.
26. Neven P, Markopoulos C, Tanner M et al. The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: First-year results from the compliance of aromatase inhibitors assessment in daily practice through educational approach (CARIATIDE) study. Breast 2014;23:393–399.
27. Yu KD, Zhou Y, Liu GY et al. A prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving patients’ persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancer. Breast Cancer Res Treat 2012;134:307–313.
28. Day R, Ganz PA, Costantino JP. Tamoxifen and depression: more evidence from the National Surgical Adjuvant Breast and Bowel Project’s Breast Cancer Prevention (P-1) Randomized Study. J Natl Cancer Inst 2001;93:1615–1623.
29. Ohsumi S, Shimozuma K, Ohashi Y et al. Healthrelated quality of life and psychological distress of breast cancer patients after surgery during a phase III randomized trial comparing continuation of tamoxifen with switching to anastrozole after adjuvant tamoxifen for 1-4 years: N-SAS BC 03. Breast Cancer Res Treat 2011;127:143–152.
30. Takei H, Ohsumi S, Shimozuma K et al. Healthrelated quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-SAS BC 04). Breast Cancer Res Treat 2012;133: 227–236.
31. Taira N, Iwata H, Hasegawa Y et al. Healthrelated quality of life and psychological distress during neoadjuvant endocrine therapy with letrozole to determine endocrine responsiveness in postmenopausal breast cancer. Breast Cancer Res Treat 2014;145:155–164.
32. Cella D, Fallowfield L, Barker P et al. Quality of life of postmenopausal women in the ATAC (“Arimidex”, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for early breast cancer. Breast Cancer Res Treat 2006;100:273–284.
33. Muss HB, Tu D, Ingle JN et al. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. J Clin Oncol 2008;26:1956–1964.
34. Jones SE, Cantrell J, Vukelja S et al. Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: Report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy. J Clin Oncol 2007;25:4765–4771.
35. Ganz PA. Assessing the quality and value of quality-of-lifemeasurement in breast cancer clinical trials. J Natl Cancer Inst 2011;103:196–199.